PubMed Health⌕ Search

Biomedical subjects

Ellen Hoffmann

Publications and source records attributed to Ellen Hoffmann.

17 recordsLinked to original sources
PubMed2006

New insights into the initiation of atrial fibrillation: a detailed intraindividual and interindividual analysis of the spontaneous onset of atrial fibrillation using new diagnostic pacemaker features.

BACKGROUND: This study investigated onset scenarios of atrial fibrillation (AF), the first phase of the Atrial Fibrillation Therapy (AFT) trial, to determine potential arrhythmogenic triggers as targets for atrial pacing algorithms that have been proposed for prevention of AF. METHODS AND RESULTS: Ninety-eight patients (58 men; age 65+/-11 years) with recurrent, symptomatic, drug-refractory AF and a conventional pacemaker indication in 31 of 98 received a dual-chamber pacemaker. Using novel diagnostic pacemaker features AF onset scenarios were prospectively evaluated in 612 AF episodes during a 2-month monitoring period, with atrial pacing limited to 40 bpm. The most common onset scenario was premature atrial complexes (PACs) before AF (48% onsets per patient), followed by bradycardia (33%), sudden onset (17%), and tachycardia (0%). Combinations of onset scenarios were frequent (median 2 different scenarios per patient). A main study finding was the significance of repetitive AF, with 33% of onsets per patient being initiated within 5 minutes of a previous AF episode. Sudden onsets were more frequent among patients with than without repetitive AF (24% versus 0% onsets per patient, P=0.011), whereas the proportion of PACs before AF was not statistically different (50% versus 37%, P=0.52); however, patients with repetitive AF had more PACs per hour (72 versus 29, P=0.023) and a higher number of AF episodes per day (17 versus 0, P=0.001) and were more likely to have at least 1 PAC-related onset (90% versus 53%, P<0.0001). CONCLUSIONS: Novel diagnostic pacemaker features allowed a detailed individual analysis of rate and rhythm changes before AF and thus uncovered a substantial intraindividual and interindividual variability of AF onset scenarios.

Aged↗
PubMed2006

Rationale and design of a randomized clinical trial to assess the role of overdrive and triggered prevention pacing therapies in reducing atrial fibrillation: the Study of Atrial Fibrillation Reduction (SAFARI).

BACKGROUND: Rhythm control in selected patients diagnosed with paroxysmal atrial fibrillation (AF) remains a clinically important goal. The role of pacing therapies for maintaining that goal remains unclear, despite considerable study effort. Several pacing strategies have been evaluated to treat AF, including various prevention pacing therapies (PPTs) designed to suppress known triggers of AF. The inconsistent results and difficulty interpreting the results of past studies stems in part from variability in trial designs, patient populations, and end points. METHODS: The SAFARI is the largest, multicenter, prospective, randomized clinical trial that aims to address many of the design limitations of previous trials to delineate better the role of PPTs. The primary end point for the study is total AF burden as reported by the device. Patients are selected to include only those with paroxysmal AF and to exclude those without documented arrhythmias. A 1-month postimplant lead stabilization period followed by a 3-month run-in period is incorporated into the design to help exclude patients with no AF after implantation or patients in whom the accuracy of the device reported AF burden is suspect. A suite of 6 PPTs is used to treat multiple different triggers of arrhythmia. Data will be gathered for 10 months. Enrollment of 546 patients was completed in January 2005; patient follow-up visits are expected to be completed in November 2005. CONCLUSION: By using a study design that addresses the limitations of previous trials, SAFARI will help significantly refine our understanding of the role of pacing to prevent AF.

Atrial Fibrillation↗
PubMed2006

Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions Part I: Supraventricular arrhythmias and pacemakers.

This document by the Study Group on Sports Cardiology of the European Society of Cardiology extends on previous recommendations for sports participation for competitive athletes by also incorporating guidelines for those who want to perform recreational physical activity. For different supraventricular arrhythmias and arrhythmogenic conditions, a description of the relationship between the condition and physical activity is given, stressing how arrhythmias can be influenced by exertion or can be a reflection of the (patho)physiological cardiac adaptation to sports participation itself. The following topics are covered in this text: sinus bradycardia; atrioventricular nodal conduction disturbances; pacemakers; atrial premature beats; paroxysmal supraventricular tachycardia without pre-excitation; pre-excitation, asymptomatic or with associated arrhythmias (i.e. Wolff-Parkinson-White syndrome); atrial fibrillation; and atrial flutter. A related document discusses ventricular arrhythmias, channelopathies and implantable cardioverter defibrillators.

Cardiac Pacing, Artificial↗
PubMed2006

Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part II: ventricular arrhythmias, channelopathies and implantable defibrillators.

This consensus paper on behalf of the Study Group on Sports Cardiology of the European Society of Cardiology follows a previous one on guidelines for sports participation in competitive and recreational athletes with supraventricular arrhythmias and pacemakers. The question of imminent life-threatening arrhythmias is especially relevant when some form of ventricular rhythm disorder is documented, or when the patient is diagnosed to have inherited a pro-arrhythmogenic disorder. Frequent ventricular premature beats or nonsustained ventricular tachycardia may be a hallmark of underlying pathology and increased risk. Their finding should prompt a thorough cardiac evaluation, including both imaging modalities and electrophysiological techniques. This should allow distinguishing idiopathic rhythm disorders from underlying disease that carries a more ominous prognosis. Recommendations on sports participation in inherited arrhythmogenic conditions and asymptomatic gene carriers are also discussed: congenital and acquired long QT syndrome, short QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular cardiomyopathy and other familial electrical disease of unknown origin. If an implantable cardioverter defibrillator is indicated, it is no substitute for the guidelines relating to the underlying pathology. Moreover, some particular recommendations for patients/athletes with an implantable cardioverter defibrillator are to be observed.

Arrhythmias, Cardiac↗
PubMed2005

Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology.

The 1996 American Heart Association consensus panel recommendations stated that pre-participation cardiovascular screening for young competitive athletes is justifiable and compelling on ethical, legal, and medical grounds. The present article represents the consensus statement of the Study Group on Sports Cardiology of the Working Group on Cardiac Rehabilitation and Exercise Physiology and the Working Group on Myocardial and Pericardial diseases of the European Society of Cardiology, which comprises cardiovascular specialists and other physicians from different European countries with extensive clinical experience with young competitive athletes, as well as with pathological substrates of sudden death. The document takes note of the 25-year Italian experience on systematic pre-participation screening of competitive athletes and focuses on relevant issues, mostly regarding the relative risk, causes, and prevalence of sudden death in athletes; the efficacy, feasibility, and cost-effectiveness of population-based pre-participation cardiovascular screening; the key role of 12-lead ECG for identification of cardiovascular diseases such as cardiomyopathies and channelopathies at risk of sudden death during sports; and the potential of preventing fatal events. The main purpose of the consensus document is to reinforce the principle of the need for pre-participation medical clearance of all young athletes involved in organized sports programmes, on the basis of (i) the proven efficacy of systematic screening by 12-lead ECG (in addition to history and physical examination) to identify hypertrophic cardiomyopathy-the leading cause of sports-related sudden death-and to prevent athletic field fatalities; (ii) the potential screening ability in detecting other lethal cardiovascular diseases presenting with ECG abnormalities. The consensus document recommends the implementation of a common European screening protocol essentially based on 12-lead ECG.

Adolescent↗
PubMed2005

Outcome of ablation for sustained focal atrial tachycardia in patients with and without a history of atrial fibrillation.

OBJECTIVES: The aim of this study was to determine the long-term results of ablation for sustained focal atrial tachycardia in patients with and without a history of atrial fibrillation. METHODS: A history of atrial fibrillation was documented in 25 of 111 patients (23%) with focal atrial tachycardias. We studied the results of focal ablation during a follow-up of 27 +/- 22 months. RESULTS: Enlargement of left atrium (Odds ratio 2.99) and septal origin of the atrial focus (Odds ratio 5.68) were independent predictors of coexisting atrial fibrillation. Patients with a septal origin of the focal atrial tachycardia were older (62 vs. 54 years) and had a higher rate of structural heart disease than patients with a non-septal site of origin (51 vs. 29%). A higher rate of atrial fibrillation was found in patients with anteroseptal (56%), midseptal (50%) and posteroseptal (36%) atrial tachycardias than in patients with focal atrial tachycardias arising from the crista terminalis (9%), the tricuspid (12%) and mitral annulus (0%), the ostia of thoracic veins (17%) and other right atrial (27%) and left atrial free wall sites (10%). During the follow-up, atrial fibrillation was documented in 3% of patients without preexisting atrial fibrillation. In patients with focal atrial tachycardia and a history of atrial fibrillation, at least one episode of atrial fibrillation was documented during follow-up in 64% of patients, but 60% of patients reported marked symptomatic improvement. CONCLUSION: An increased rate of coexisting atrial fibrillation was found in patients with a septal origin of focal atrial tachycardia. Ablation of the focal atrial tachycardia may eliminate both arrhythmias, but patients with a history of atrial fibrillation may still be prone to recurrences of atrial fibrillation after focal ablation.

Atrial Fibrillation↗
PubMed2005

Different patterns of the fall of impedance as the result of heating during ostial pulmonary vein ablation: implications for power titration.

BACKGROUND: A variety of strategies have been proposed to avoid the risks of pulmonary vein ablation for atrial fibrillation. The fall of impedance during radiofrequency catheter ablation can be used as a real time measure of tissue heating. The aim of this study was to analyze the impedance fall during ostial pulmonary vein ablation and to evaluate whether adjusting power to the fall of impedance may contribute to a reduction of the risk of complications. METHODS: Analysis of biophysical parameters of ablation and determination of ostial diameters during follow-up were performed in 70 patients undergoing impedance-guided segmental ostial pulmonary vein ablation. Repeat radiographic angiography, local electrograms, and baseline impedance were the criteria to define the position of the 4-mm electrode tip at atrial sites or inside the proximal pulmonary veins. RESULTS: Energy application inside the proximal pulmonary veins led to an increased impedance fall inside the first 5-10 mm of the pulmonary veins (1.1 +/- 0.5 Omega/W) as compared to ablation at atrial sites (0.7 +/- 0.3 Omega/W) (P < 0.01). The analysis of temperature and impedance fall during ostial ablation demonstrated an increased impedance fall with heating at sites inside the proximal pulmonary veins (1.5 +/- 0.6 Omega/ degrees C) as compared to atrial sites (1.2 +/- 0.5 Omega/ degrees C) (P < 0.001). The regression lines analyzing these correlations indicated that adjusting power to a maximum impedance fall of 20 Omega would limit heating at pulmonary venous sites to lower temperatures (average maximum temperature: 48 degrees C) than at atrial sites (average maximum temperature: 63 degrees C). The ablation strategy used for segmental ostial ablation in 70 patients, which involved power limitation to a maximum impedance fall of 20 Omega, allowed isolation of 89% of targeted pulmonary veins with a low rate of impedance rises (0.3% of applications). No pulmonary vein stenoses >30% were detected by follow-up computed tomography analysis. CONCLUSIONS: An increased impedance fall as the result of heating during ostial ablation was found inside the proximal pulmonary veins as compared to atrial sites. Adjusting power to the fall of impedance during segmental ostial pulmonary vein ablation contributes to the prevention of overheating inside the pulmonary veins and may lower the risk of coagulum formation and pulmonary vein stenosis.

Atrial Fibrillation↗
PubMed2004

Immediate Risk-Stratification Improves Survival (IRIS): study protocol.

BACKGROUND: To date, the implantable cardioverter-defibrillator (ICD) has been shown to be effective for primary prevention of sudden cardiac death only in selected groups of patients in the chronic phase after myocardial infarction. METHODS AND RESULTS: The Immediate Risk-Stratification Improves Survival (IRIS) Study compares ICD therapy with no ICD therapy in selected high risk patients early after myocardial infarction. Special emphasis is placed on optimal acute and long term medical therapy in all patients including metoprolol CR/ZOK. The hypothesis is tested that use of the ICD reduces overall mortality. For that purpose, consecutive acute ST elevation or non-ST elevation myocardial infarction patients are collected in a registry. From this denominator, patients are screened, and enrolled early after myocardial infarction (day 5 to day 31) if they exhibit both a reduced left ventricular ejection fraction < or =40% and a heart rate > or =100 bpm on the first available electrocardiogram (criterion I), or non-sustained ventricular tachycardia at a rate > or =150 bpm during Holter (criterion II). CONCLUSIONS: IRIS is a large scale prospective, randomized trial to evaluate the benefit of ICD therapy for reduction of total mortality in patients considered at high risk of sudden death early after acute myocardial infarction.

Clinical Protocols↗
PubMed2004

Application of radiofrequency energy in surgical and interventional procedures: are there interactions with ICDs?

During surgical and interventional procedures, interference may occur between ICDs and electrical cautery or with the application of RF energy. This may lead to the false induction of ICD therapies or could even result in device malfunction, which represents a potential perioperative hazard for the patient. This study analyzed the intraoperative interactions in 45 consecutive ICD patients in reference to different surgical and interventional procedures. A total of 33 surgical operations (general surgery [n = 14], urologic [n = 5], abdominal [n = 10], gynecological [n = 2], thoracic [n = 1], neurosurgical [n = 1]) and 12 interventional therapies (RF catheter ablation [n = 10], endoscopic papillotomy [n = 2]) were performed. The ICD devices were all located in left pectoral position and consisted of 25 single and 20 dual chamber defibrillators. During the procedure, tachyarrhythmia detection (VF 296 +/- 20 ms, VT 376 +/- 49 ms) of the devices was maintained active (monitoring mode), only ICD therapies were inactivated. The indifferent electrode of the electrical cauter/RF generator was placed in standard positions (right/left mid-femoral position [n = 27/8], thoracic spine area [n = 10]). After the procedure, the ICD memory was checked for detections and for changes in the programming. There was no oversensing, reprogramming, or damage of any defibrillator caused by RF energy. Despite the lack of undesired interactions, ICDs should be inactivated preoperatively to assure maximum patient safety. However, should inactivation not be possible, or the achievement uncertain, electromagnetic interference is highly unlikely.

Adult↗
PubMed2003

Prevention of sustained ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators-the PREVENT study.

BACKGROUND: In patients with implantable cardioverter-defibrillators (ICDs), 25 to 45% of tachyarrhythmia episodes were initiated by short-long-short RR intervals. METHODS: The prospective multi-center PREVENT study randomized patients implanted with ICDs capable of atrioventricular pacing, in order to compare-using a cross-over design with two 3-month treatment periods-the benefits of 'rate smoothing' (RS) as a 'pause-prevention algorithm' for the prevention of ventricular tachyarrhythmias. RESULT: Follow-up included 219 patients with implanted ICDs, of whom 153 were eligible for analysis as per protocol. Fifty-seven of these patients (38%) had documented episodes of ventricular tachyarrhythmias during the six months follow-up. The total number of sustained ventricular tachyarrhythmia episodes was reduced from 358 with RS Off to 145 with RS On. RS was effective in reducing the number of short-long-short induced sustained ventricular episodes from 100 with RS Off to 40 with RS On. The Wilcoxon-Mann-Whitney point estimator equals 0.66 with a 95% confidence interval from 0.51 to 0.82 (relevant superiority; corresponding p = 0.039). There were no proarrhythmic effects due to rate smoothing within the scope of this study. CONCLUSIONS: 'Rate smoothing' significantly reduced sustained ventricular tachyarrhythmias in ICD patients. There is a relevant superiority of the treatment during the early six months of follow-up.

Aged↗
PubMed2003

Electroanatomic mapping of endocardial right ventricular activation as a guide for catheter ablation in patients with arrhythmogenic right ventricular dysplasia.

Arrhythmogenic right ventricular dysplasia is a structural heart disease characterized by fibrofatty degeneration of right ventricular myocardium and arrhythmias of right ventricular origin. The aim of this study was to characterize endocardial right ventricular activation by electroanatomic mapping as a guide for catheter ablation in patients with arrhythmogenic right ventricular dysplasia. Electroanatomic mapping and entrainment procedures were performed in 5 patients with arrhythmogenic right ventricular dysplasia. Endocardial mapping during ventricular tachycardia demonstrated a focal activation pattern with radial spreading of activation from a site of earliest ventricular activation in all directions. Right ventricular activation time (127 +/- 34 ms) was markedly shorter than tachycardia cycle length (415 +/- 92 ms). The site of earliest ventricular activation was found in an aneurysmal outflow tract (n = 2), at the border of aneurysms near the tricuspid annulus (n = 2), and at the apex of the right ventricle (n = 1). Entrainment mapping criteria of these areas of earliest endocardial activity were consistent with exit sites of a reentrant circuit in an area of abnormal myocardium. Fractionated potentials were found 61 +/- 29 ms before the onset of the QRS complex at these sites. Catheter ablation rendered the "clinical" ventricular tachycardia noninducible in four patients but "nonclinical" faster ventricular tachycardias were inducible in three patients. During the follow-up of 7 +/- 3 months after ablation, the frequency of therapies in 4 patients with an implantable cardioverter defibrillator decreased from 49 +/- 61 episodes per month before ablation, to 0.3 +/- 0.5 episodes per month after ablation (P < 0.05). Electroanatomic mapping during ventricular tachycardia facilitates localization of exit sites in relation to aneurysms in diseased right ventricle and may guide catheter ablation in patients with arrhythmogenic right ventricular dysplasia.

Arrhythmogenic Right Ventricular Dysplasia↗
PubMed2003

Radiofrequency catheter ablation: different cooled and noncooled electrode systems induce specific lesion geometries and adverse effects profiles.

The success and safety of standard catheter radiofrequency ablation may be limited for ablation of atrial fibrillation and ventricular tachycardia. The aim of this study was to characterize and compare different cooled and noncooled catheter systems in terms of their specific lesion geometry, incidence of impedance rise, and crater and coagulum formation to facilitate appropriate catheter selection for special indications. The study investigated myocardial lesion generation of three cooled catheter systems (7 Fr, 4-mm tip): two saline irrigation catheters with a showerhead-type electrode tip (sprinkler) and a porous metal tip and an internally cooled catheter. Noncooled catheters (7 Fr) had a large tip electrode (8 mm) and a standard tip electrode (4 mm). RF energy was delivered on isolated porcine myocardium superfused with heparinized pig blood (37 degrees C) at power settings of 10-40 W. Both irrigated systems were characterized by a large lesion depth (8.1 +/- 1.6 mm) and a large lesion diameter (13.8 +/- 1.6 mm). In comparison, internally cooled lesions showed a similar lesion depth (8.0 +/- 1.0 mm), but a significantly smaller lesion diameter (12.3 +/- 1.2 mm,P = 0.04). Large tip lesions had a similar lesion diameter (14.5 +/- 1.6 mm), but a significantly smaller lesion depth (6.3 +/- 1.0 mm,P = 0.002) compared to irrigated lesions. However, lesion volume was not significantly different between the three cooled and the large tip catheter. To induce maximum lesion size, power requirements were three times higher for the irrigation systems and two times higher for the internally cooled and the large tip catheter compared to the standard catheter. Impedance rise was rarest with irrigated and large tip ablation. In case of impedance rise crater formation was a frequent observation (61-93%). Irrigated catheters prevented coagulum formation most effectively. Irrigated rather than internally cooled ablation appears to be most adequate for the induction of deep and long lesions at a low rate of impedance rise and thrombus formation. Large tip ablation may be feasible for the creation of long linear lesions, however, with an increased risk of thrombus formation.

Animals↗
PubMed2003

Transvenous defibrillation leads: high incidence of failure during long-term follow-up.

INTRODUCTION: Patients with implantable cardioverter defibrillators (ICD) critically depend on correct functioning of their system. The aim of this study was to determine the incidence and clinical presentation of transvenous ICD lead failures during long-term follow-up. METHODS AND RESULTS: The study group consisted of 261 consecutive patients who received Medtronic right ventricular polyurethane transvenous leads (models 6884, 6966, 6936) between 1990 and 1998 as part of an abdominal (n = 70) or pectoral (n = 191) ICD system. During mean follow-up of 4.0 +/- 2.6 years, 31 patients (12%) developed a lead-related sensing failure with oversensing of artifacts. All failures except two were compatible with an insulation defect and occurred late after ICD placement (6.0 +/- 1.8 years after implant). Lead survival decreased from 98% at 4-year follow-up to only 62% at 8-year follow-up. Lead survival was not related to patient age, sex, venous lead implantation route, or device implantation site. In 26 (87%) of 31 patients, a sensing defect resulted in inappropriate detection of ventricular fibrillation and subsequent delivery of 3 +/- 3 (range 1-11) inappropriate shocks in 19 (61%) of 31 patients. Device interrogation showed artifacts classified as nonsustained ventricular tachycardia in 21 patients, 40 +/- 43 days before clinically relevant failure of the system. One patient with a subclavian crush syndrome required resuscitation because of undersensing of true ventricular fibrillation. CONCLUSION: Transvenous polyurethane ICD leads showed a high rate of lead insulation failure late after implantation with frequent inappropriate shock deliveries. Close follow-up is mandatory in patients with these leads. Automated device control features with patient alert function integrated into new devices may contribute to early detection of lead failure.

Adult↗
PubMed2002

Pulmonary vein bigeminy: electrophysiological characteristics and results of catheter ablation.

UNLABELLED: Pulmonary vein bigeminy is the pair of a second, late and ectopic pulmonary vein potential following atrial far-field activation and a first passive pulmonary vein potential during sinus rhythm. The aim of this study was to determine the electrophysiological characteristics of pulmonary vein bigeminy and to evaluate its relevance as a trigger for paroxysmal atrial fibrillation. METHODS AND RESULTS: Pulmonary vein bigeminy was recorded in 8 of 45 patients (18%) who underwent mapping of pulmonary veins for ablation of focal atrial fibrillation. The premature ectopic pulmonary vein potentials were conducted to the atria in 5 patients and were not conducted (concealed bigeminy) in 3 patients. The coupling interval of the ectopic pulmonary vein potential to the preceding atrial signal during sinus rhythm was significantly longer in patients with conducted bigeminy (375 +/- 25 ms) than with concealed bigeminy (230 +/- 17 ms). The pulmonary vein bigeminy was driven by coronary sinus pacing with the pacing cycle length at lower stimulation rates and was suppressed by overdrive pacing. Coronary sinus pacing led to a separation of the first pulmonary vein potential from the atrial signal but the interval between the atrial signal and the second pulmonary vein potential remained unchanged. Focal ablation at the site of earliest ectopic pulmonary vein activity in 5 patients induced rapid repetitive firing before elimination of the pulmonary vein bigeminy. Ostial disconnection of the arrhythmogenic pulmonary vein in 3 patients was associated with elimination of the pulmonary vein bigeminy. During the follow-up of 9 +/- 5 months after ablation of the pulmonary vein bigeminy, 5 of the 8 patients (63%) were free of atrial fibrillation without antiarrhythmic medication. CONCLUSIONS: The response of pulmonary vein bigeminy to atrial pacing and ostial ablation suggests that pulmonary vein bigeminy depends on an intact electrophysiological breakthrough between the left atrium and the pulmonary vein. Ablation targeting the pulmonary vein bigeminy is a possible limited approach for this subgroup of patients with paroxysmal atrial fibrillation.

Atrial Fibrillation↗
PubMed2002

Clinical experience with electroanatomic mapping of ectopic atrial tachycardia.

The aim of this study was to evaluate the clinical use of a new three-dimensional mapping system as a guide for catheter ablation of ectopic atrial tachycardia. A series of 42 consecutive patients with drug refractory ectopic atrial tachycardia was studied in a prospective observational trial with the electroanatomic mapping system CARTO. The arrhythmogenic focus was found in the right atrium in 30 patients and in the left atrium in 12 patients. The construction of a complete electroanatomic map of the right or left atrium was possible in 37 of 42 consecutive patients with ectopic atrial tachycardia. Mean activation time of the right atrium, including the proximal coronary sinus, was 94 +/- 25 ms for right atrial tachycardias; left atrial activation time during left atrial tachycardias was 86 +/- 17 ms. Average mapping time was 30 minutes for right atrial tachycardias and 22 minutes for left atrial tachycardias, allowing the collection of 86 +/- 50 and 65 +/- 28 catheter positions, respectively. The size of the area of earliest atrial activation calculated from the electroanatomic map amounted to 0.6 +/- 0.4 cm2 in right atrial tachycardias and 1.0 +/- 0.9 cm2 in left atrial tachycardias. In the right atrium the most common locations of the 33 arrhythmogenic foci in 30 patients were the high or mid-lateral right atrium (n = 10) and the inferoparaseptal region near the coronary sinus ostium (n = 7). Ectopic left atrial foci were most commonly located in an inferior position near the mitral annulus (n = 5) and in proximity to the ostium of the pulmonary veins (n = 4). Biatrial electroanatomic mapping allowed visualization of earliest right atrial activation during left atrial tachycardia at the high interatrial septum or near the coronary sinus ostium. Catheter ablation was successful in 85% of right atrial tachycardias and 82% of left atrial tachycardias. In patients with ectopic atrial tachycardia electroanatomic mapping is a safe and feasible technique that allows three-dimensional visualization of the automatic focus in a precise anatomic reconstruction of the atria. This novel mapping technology facilitates catheter ablation of complex ectopic atrial tachycardia.

Adolescent↗
PubMed2002

Suppression of concealed pulmonary vein bigeminy by atrial pacing in a patient with paroxysmal atrial fibrillation.

Concealed pulmonary vein bigeminy, as a pair of a pulmonary vein spike potential within a fragmented far-field atrial electrogram and a premature ectopic pulmonary vein spike potential with exit block, was continuously recorded in a patient with paroxysmal AF. Atrial pacing suppressed the breakthrough from the left atrium to the pulmonary vein, thus preventing the conducted and the premature ectopic pulmonary vein potentials. Atrial pacing induced conduction block between the left atrium and the arrhythmogenic pulmonary vein might be a possible explanation for the prevention of paroxysmal AF by atrial pacing.

Atrial Fibrillation↗